http://www.gwpharm.co.uk/sativex3.asp
Sativex
To assist potential prescribers the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Public Information Report on Sativex®, which can be found on the MHRA website. Click here to download the full MHRA report and here to download a supporting Question and Answer (Q&A) document.
Sativex® remains an unlicensed medicine in the UK and, as a cannabis-based medicine, is currently a Schedule 1 Controlled Drug. Previously doctors were required to obtain a licence to prescribe Sativex® from the Home Office but this is no longer a requirement as the Home Office has issued an open general licence permitting any doctor wishing to prescribe Sativex® to do so under the Misuse of Drugs Act. This licence also permits pharmacists to dispense Sativex® and permits patients to possess Sativex® if dispensed in accordance with a bona fide prescription.
As an unlicensed medicine, the decision to prescribe Sativex® for a patient is entirely at the discretion of the prescribing doctor and at their direct responsibility.
If you are a doctor in the UK and would like further information on Sativex® please contact either GW Pharmaceuticals or Bayer Healthcare using the details below:
GW Pharmaceuticals
Tel: 01980 557026
Fax: 01980 557027
Email: enquiries@gwpharm.com
Bayer Healthcare
Tel (during working hours): 01635 563 116
Tel (out of working hours): 01635 563 000
Fax: 01635 563 657
Email: medical.science@bayer.co.uk
